Epcoritamab-bysp (Epkinly) — CPB 1034 | AETNA Coverage Update

Aetna modified CPB 1034 for epcoritamab-bysp (Epkinly), effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its coverage policy for epcoritamab-bysp (Epkinly) under CPB 1034 in the Aetna epcoritamab-bysp coverage policy governing commercial medical plans. The primary billing codes affected are HCPCS J9321 (injection, epcoritamab-bysp, 0.16 mg) and CPT 96401 (chemotherapy administration, subcutaneous or intramuscular). If your team bills J9321 for Epkinly or handles oncology revenue cycle for lymphoma patients, this update directly changes your precertification workflow.

Quick-Reference Table

Aetna Epcoritamab-bysp Coverage Criteria and Medical Necessity Requirements 2025

The CPB 1034 Aetna system policy requires precertification for every claim — no exceptions. Aetna will not reimburse epcoritamab-bysp without it. This applies to all participating providers and members in applicable Aetna commercial plan designs.

Precertification is a hard stop here, not a soft recommendation. The real issue is that without prior authorization in place before the date of service, your J9321 claim is heading for a claim denial. At a per-unit cost of a drug in this class, a single denied claim is a meaningful financial event.

To get prior authorization, call (866) 752-7021 or fax (888) 267-3277. For Statement of Medical Necessity (SMN) precertification forms, visit the Aetna Specialty Pharmacy Precertification page.

The ICD-10 diagnosis codes eligible under this coverage policy span 154 codes across follicular lymphoma (C82.xx) and related lymphoma categories. Your medical necessity documentation needs to tie the patient's specific diagnosis code to the approved ICD-10 list. A mismatch between the billed diagnosis and the covered code set is one of the fastest routes to a denial on a drug this expensive.

For Medicare-covered patients, this CPB does not apply. Aetna directs Medicare criteria to a separate Medicare Part B step-therapy process. If you bill Medicare Advantage plans through Aetna, confirm which policy governs before you bill — don't assume CPB 1034 covers those patients.

Coverage Indications at a Glance

Aetna Epcoritamab-bysp Billing Guidelines and Action Items 2025

The effective date of September 26, 2025 is already here. If you haven't updated your workflows, do it now.

1. Confirm precertification is active for every open Epkinly case.
Check every patient currently on epcoritamab-bysp. If a prior authorization wasn't obtained under the updated CPB 1034 criteria, get it before you bill. A lapsed or missing precertification is an automatic denial.

2. Use the correct precertification contact, every time.
Call (866) 752-7021 or fax (888) 267-3277. Don't route these through a general authorization line. Wrong contact means delayed auth, which means delayed reimbursement.

3. Bill J9321 at the correct unit.
HCPCS J9321 is billed per 0.16 mg of epcoritamab-bysp. Get your unit math right before submission. Undercoding loses money. Overcoding creates a compliance exposure. Check your charge capture against the actual dose administered.

4. Pair J9321 with CPT 96401 for the administration component.
CPT 96401 covers subcutaneous or intramuscular chemotherapy administration for non-hormonal anti-neoplastic agents. Epkinly is administered subcutaneously. Bill both codes when the drug and administration occur in your facility. Missing 96401 leaves money on the table.

5. Validate the ICD-10 diagnosis code before submission.
With 154 covered diagnosis codes under this policy, most follicular lymphoma and related lymphoma diagnoses are covered. But "most" isn't "all." Pull the specific ICD-10 code from the patient's chart and confirm it's on the covered list before the claim goes out. A C85 code where a C82 code belongs will deny.

6. Separate your commercial and Medicare billing workflows.
CPB 1034 covers Aetna commercial plans only. Medicare patients follow a different path entirely. Flag Aetna Medicare Advantage patients at intake and route them to your Medicare billing guidelines process before precertification is requested.

7. Get your SMN forms from the right source.
Use the Aetna Specialty Pharmacy Precertification page for Statement of Medical Necessity forms. Using an outdated form delays the auth. It's a small thing that causes big backlogs.

If your Epkinly volume is high and you're billing across multiple Aetna plan types, loop in your compliance officer before September 26, 2025. The boundary between commercial and Medicare Advantage plans creates real exposure if the wrong policy governs a claim.

CPT, HCPCS, and ICD-10 Codes for Epcoritamab-bysp (Epkinly) Under CPB 1034

Covered HCPCS Codes (When Selection Criteria Are Met)

Other CPT Codes Related to CPB 1034

Key ICD-10-CM Diagnosis Codes

The following codes represent the covered diagnosis set under CPB 1034. All 154 codes are follicular lymphoma and related B-cell lymphoma categories. The table below includes the full set from the policy data.

The full policy lists 154 ICD-10-CM codes. The policy data provided includes the C82.xx follicular lymphoma series above. For the complete covered diagnosis list, review CPB 1034 directly on the Aetna policy source.

A Note on the ICD-10 Code Volume

154 covered diagnosis codes is a large set. That breadth tells you something useful: Aetna built this coverage policy to cover the full clinical scope of follicular lymphoma staging and site coding, not just a narrow indication. The C82 series covers follicular lymphoma grade 1 through 3b, by nodal site and unspecified variants.

Don't let the volume create false confidence. The right 6-character code still matters. If your coder defaults to C82.9 (unspecified) when the chart supports a specific grade and site, you're leaving specificity on the table — and specificity is exactly what Aetna's precertification reviewers look for when they assess medical necessity.